Extracellular Fluid in Resistant Hypertension

St George's, University of London32 enrolled

Overview

The optimal treatment of drug resistant (defined as BP\> 140/85 despite three anti-hypertensive drugs including a diuretic) is not well defined. This study aims to test the hypothesis that resistant hypertension is caused by excessive expansion of extracellular fluid volume. A secondary objective is to study which of three different antihypertensive drugs would be most useful in drug resistant hypertension.

Following recruitment subjects will have ECV measured by 51Cr-EDTA determination of GFR, with Brochner-Mortensen correction applied. Subjects then receive the following drugs, in a randomised fashion, for a period of four weeks each, with BP \& ECV measurement at end of each period: doxazosin GITS (Cardura XL) 4 mg b.d.; frusemide 40 mg b.d.; amiloride 5 mg b.d.; placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hypertension

Interventions

Cardura XL 4 mg bdDRUG

Amiloride 5 mg bdDRUG

Furosemide 40 mg bdDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * BP \>140/85 * 3 antihypertensive drugs (ACE/ARB + calcium channel blocker + thiazide diuretic) Exclusion Criteria: * Pregnancy * Breast Feeding * Unstable heart failure * Chronic Liver Disease * Creatinine \>120 mcmol/L * Contraindication to (or intolerance of) drug used in study * BP \> 180/110

Locations (1)

Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL

London, United Kingdom

Outcomes

Primary Outcomes

Change in ECV; change in BP

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.